Transcription of WHO Drug Information
{{id}} {{{paragraph}}}
Example: marketing
WHO Drug Information
573 WHO Drug Information Vol. 31, No. 4, 2017 ContentsSafety of medicines575 Priming resource-limited countries for pharmacovigilanceNaming of medicines581 Survey about International Nonproprietary Names (INN)Safety news586 Safety warningsMiconazole oral gel ; Obeticholic acid ; Linagliptine ; Dabigatran ; Flucloxacillin ; Epoetins ; Intraocular vancomycin ; Fingolimod ; Daclizumab ; Levetiracetam ; Sodium polystyrene sulfonate ; Radium-223 dichloride 590 Known risksAmoxicillin ; Moxifloxacin ; Palivizumab ; Cladribine ; Clozapine ; Buprenorphine, methadone 591 Review outcomesFactor VIII medicines592 Reviews startedHydroxyethyl starch;Ulipristal ;Febuxostat;Flupirtine-containing products;Radium-223 593 Non-compliance with good practicesLupin Falsified medicinesFalsified Penicillin V circulating in CameroonRegulatory news594 Pre-market assessmentChina: Regulatory reforms ; : Promoting competition for complex products ;Europe: Regulators and funders meet.
577 WHO Drug Information Vol. 31, No. 4, 2017 Complex health care systems In most resourcelimited countries the public and private health care systems are
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: